1. Nanomedicine

Category Archives: Nanomedicine

Bradley Nelson : Medical MicroRobotics and NanoMedicine : Teruko Yata Memorial Lecture in Robotics – Video

Posted on by


Bradley Nelson : Medical MicroRobotics and NanoMedicine : Teruko Yata Memorial Lecture in Robotics
Brad Nelson ETH Zrich April 16, 2015 While the futuristic vision of micro and nanorobotics is of intelligent machines that navigate throughout our bodies searching for and destroying disease,...

By: cmurobotics

Original post:
Bradley Nelson : Medical MicroRobotics and NanoMedicine : Teruko Yata Memorial Lecture in Robotics - Video

World Nanomedicine Universe Discussed by Kuick Research in New Market Study Recently Published at MarketPublishers.com

Posted on by

London, UK (PRWEB) April 09, 2015

Pharmacos are developing more effective drug delivery vehicles with the aid of nanotechnology. Lack of specificity induces undue drug wastage, reduced potency and undesirable side effects during treatment. This is a serious problem, especially when a patient is suffering from cancer, where the use of chemotherapy is part of therapeutic regimen. Easy modification, customisability and product cost are set to be the major factors determining the commercial success apart from their pharmacological benefits. Heavy investments in R&D are poised to assist in identifying effective nanoparticle-based drug delivery vehicles.

Manifold nanotechnology-based devices, medicines, chips and sensors are undergoing various stages of clinical trials. To date, there are 144 nanomedicines in clinical development. The majority of the nanomedicines are in pre-clinical development phase, followed by research phase. Only a limited number of products are in the market for few indications; currently, 13 nanomedicines are commercially available in the market. Their clinical pipeline is getting stronger year by year and novel incentives are being taken by pharmacos, but the rate of commercialisation of such products is slow and the market size is still limited. To surmount these barriers, the pace of R&D alongside market introduction needs to be increased in the offing. This would help generate a big chunk of revenues, however, it will take several years for nanomedicines to receive recognition as mainstream medicines. Judging by the pace at which they are growing, nanomedicines and associated medical technologies have bright future.

New research report Global Nanomedicine Market & Pipeline Insight 2015 developed by Kuick Research is now available at MarketPublishers.com.

Report Details:

Title: Global Nanomedicine Market & Pipeline Insight 2015 Published: April, 2015 Pages: 330 Price: US$ 2,400.00 https://marketpublishers.com/report/medical_devices/other_medical_devices/global-nanomedicine-market-pipeline-insight-2015.html

The report offers a detailed guide to the worldwide nanomedicine (nanotherapeutic) marketplace. It provides deep insights into the nanomedicine mechanism, an analysis of the present-day market scenario and an overview of the nanomedicine product pipeline globally. The research report limelights the market dynamics covering major market driving factors and challenges, as well as peeps into the future development path of the sector. The study reviews the nanomedicine product clinical pipeline by indication, phase and company; discusses marketed nanomedicines by company and disease indication; sheds light on the suspended and discontinued nanomedicine clinical pipeline. The research publication delves in the competitive landscape along with profiling the major players.

Report Highlights:

More new reports by the publisher can be found at Kuick Research page.

Excerpt from:
World Nanomedicine Universe Discussed by Kuick Research in New Market Study Recently Published at MarketPublishers.com

Nanomedicine Aims New Treatments at Cancer and Dangerous Wounds

Posted on by

Working on a very small scale lets scientists give drugs abilities denied to larger molecules

Harry Campbell

A molecule of DNA, holding its blueprint for life, is about 2.5 billionths of a meter in diameter. Scientists now have the ability to push and pull and build molecules of that size, as well as to create devices that sense them with unprecedented precision. These skills, gained through painstaking work during the past decade, are leading to new medicines and ways of diagnosing disease. In this special report, Scientific American examines what nanomedicine is bringing us now, what is coming soon and what the future will likely hold.

Right now chemotherapy is a major focus, and drugs that can slip into tumors because of their fine-grained construction are showing success where other medications fail patients [see Cancer Drugs Hit Their Mark, on page 44]. Diagnostic tests are also taking advantage of the small sizes, using probes of unusually shaped DNA that can detect cancer with remarkable accuracy. Next, in the near future, patients should be able to use smart bandages made with nano-sized molecules that enhance the healing of severe woundsor that signal doctors when healing is not happening [see A Smarter Bandage, on page 47]. Further out in time, researchers hope to attach tiny molecular motors to drugs, driving them through the bloodstream to their targets [see Launch the Nanobots! on page 50]. These are feats of nanoengineering, invisible to the eye, yet they could have an outsize effect on health.

SCIENTIFIC AMERICAN ONLINE Listen to a panel talk about nanomedicine advances at ScientificAmerican.com/apr2015/nanomed-advance

This article was originally published with the title "Small Wonders."

Already have an account? Sign In

Digital Issue $5.99

Scientific American Single Issue

Special Editions Volume 23, Issue 3s

Follow this link:
Nanomedicine Aims New Treatments at Cancer and Dangerous Wounds

Targeting Dangerous Inflammation Inside Artery Plaque

Posted on by

New York, NY (PRWEB) April 03, 2015

A research team showed that a nanotherapeutic medicine can halt the growth of artery plaque cells resulting in the fast reduction of the inflammation that may cause a heart attack, according to a study led by researchers from Icahn School of Medicine at Mount Sinai and published April 3 in Science Advances.

In just one week our novel cell proliferation-specific approach successfully suppressed atherosclerotic plaque growth and inflammation in mice engineered to mimic human vascular disease, says lead study author Jun Tang, MS, a PhD student at Icahn School of Medicine at Mount Sinai. Atherosclerosis is a major cause of death around the globe, and our nanomedicine strategy promises to offer a new way to reduce the number of heart attacks and strokes.

Building upon a recent discovery by their Massachusetts General Hospital research collaborators that macrophage proliferation dictates atherosclerosis-related vessel wall inflammation, the Mount Sinai research team applied a nanomedicine strategy with a molecule of good cholesterol, or high-density lipoprotein (HDL), a naturally occurring shuttle that travels from the liver to arteries. The research team took advantage of HDLs natural travel routes, loading it with the widely-used cholesterol-lowering medication called simvastatin (Zocor), which it shuttles into arterial walls.

The simvastatin-loaded nanoparticles, named S-HDL, work by targeting inflamed immune cells called macrophages within high-risk arterial plaques. These macrophages become laden with cholesterol and start proliferating in plaques, thereby increasing inflammation. This lipid-driven inflammatory process drives atherosclerotic plaque buildup and rupture leading to a heart attack or stroke.

Since patients hospitalized after heart attack or stroke have a high recurrence rate of up to 20 percent within three years, the researchers also tested the possible benefits of adding an eight-week regimen of oral statins after the one-week S-HDL nanotherapy. Mice study results showed superior long-term therapeutic benefits of a combined total nine-week S-HDL and oral statins regimen, by first rapidly reducing plaque inflammation and then continuously keeping it suppressed.

We envision our S-HDL nanomedicine therapy could be translated quickly to human clinical trials as a short-term infusion therapy for heart attack and stroke patients to rapidly suppress plaque inflammation, which can be sustained using current standard of care oral statin medication, says Zahi Fayad, PhD, Professor of Radiology and Director of the Translational and Molecular Imaging Institute at Icahn School of Medicine at Mount Sinai.

Nanotherapeutically inhibiting local macrophage proliferation is possible and we can effectively apply it to treat inflammation inside arteries. Collectively, our results demonstrate that the two-step regimen not only reduces macrophage accumulation but also reduces the expression of key genes linked to inflammation in this cell type, says senior study author Willem Mulder, PhD, Associate Professor of Radiology in the Translational and Molecular Imaging Institute at the Icahn School of Medicine at Mount Sinai.

Researchers look forward to translating their promising mice study findings to larger animal models and human clinical trials in the near future.

This study was funded by the NHLBI, NIH Program of Excellence in Nanotechnology (PEN) Award (HHSN368201000045C, to Z.A.F); NIH grants R01 HL118440 (W.J.M.M.), R01 HL125703 (W.J.M.M.), R01 CA155432 (W.J.M.M.), R01 EB009638 (Z.A.F.); Harold S. Geneen Charitable Trust Award (Z.A.F.); and American Heart Association Founders Affiliate Predoctoral Award (13PRE14350020-Founders, to J.T.)

More here:
Targeting Dangerous Inflammation Inside Artery Plaque

Alcor: FAQ – Technical – Cryonics: Alcor Life Extension …

Posted on by

Index - 1.General - 2.Technical - 3.Ethical - 4.Spiritual 5.Financial - 6.Membership - 7.Misinformed See also Scientists' Cryonics FAQ

Q: What are nanotechnology and nanomedicine?

A: Molecular nanotechnology is an emerging technology for manufacturing and manipulating matter at the molecular level. The concept was first suggested by Richard Feynman in 1959. The theoretical foundations of molecular nanotechnology were developed by K. Eric Drexler, Ralph Merkle, and others in the 1980s and 1990s. More recently the future medical applications of nanotechnology have been explored in detail by Robert Freitas in his books, Nanomedicine Vol. I (Basic Capabilities) and Nanomedicine Vol. IIA (Biocompatibility). These scientists have concluded that the mid to late 21st century will bring an explosion of amazing capabilities for analyzing and repairing injured cells and tissues, similar to the information processing revolution that is now occurring. These capabilities will include means for repairing and regenerating tissue after almost any injury provided that certain basic information remains intact. A non-technical overview of nanotechnology, including an excellent chapter on cryonics ("biostasis"), is available in Eric Drexler's book, Engines of Creation.

|top|

Q: Won't memories be lost if brain electrical activity stops?

A: Short-term memory depends on electrical activity. However long-term memory is based on durable molecular and structural changes within the brain. Quoting from the Textbook of Medical Physiology by Arthur C. Guyton (W.B. Saunders Company, Philadelphia, 1986):

We know that secondary memory does not depend on continued activity of the nervous system, because the brain can be TOTALLY INACTIVATED (emphasis added) by cooling, by general anesthesia, by hypoxia, by ischemia, or by any method, and yet secondary memories that have been previously stored are still retained when the brain becomes active once again.

This is known from direct clinical experience with surgical deep hypothermia, for which complete shutdown of brain electrical activity (electrocortical silence) is not only permissible, but desirable for good neurological outcome.

Follow this link:
Alcor: FAQ - Technical - Cryonics: Alcor Life Extension ...

Researchers Use Nanoparticles to Selectively Target Tumor Cells in Two Cancer Models

Posted on by

Contact Information

Available for logged-in reporters only

Newswise Nanoparticles hold great promise for cancer diagnostics and therapies, but only to the extent that they can be selectively guided to tumors and cancer cells. Leading a multidisciplinary group from Dartmouth College, Karl E. Griswold, PhD published, "Antibody-mediated targeting of iron oxide nanoparticles to the Folate receptor alpha increases tumor cell association in vitro and in vivo," in the International Journal of Nanomedicine, which follows closely the publication of "Tumor Cell Targeting by Iron Oxide Nanoparticles is Dominated by Different Factors in Vitro versus in Vivo," published in PLOS ONE.

"The ultimate utility of anti-cancer nanoparticle technologies will depend in large part on their capacity to selectively home to cancer cells," explained Griswold. "Achieving optimal targeting of nanoparticles in clinically relevant scenarios remains a key challenge for researchers in this space."

The in vivo environment is enormously complex, and there exists an extensive array of variables that determine distribution and cellular targeting of nanoparticles in the body. Homing of nanoparticles to tumors is dependent upon parameters such as nanoparticle size and composition, molecular targeting, surface chemistry, route of administration, cancer cell type, and tumor location.

Using carefully designed and rigorously validated functional nanomaterials, the Dartmouth team pursued a systematic study of those variables in xenograft models of both breast and ovarian human cancers. The in vivo studies showed that antibody targeted iron oxide nanoparticles accumulated in tumor tissues following systemic administration, whereas non-targeted nanoparticles failed to show any detectable tumor association. Importantly, molecular targeting not only localized nanoparticles to tumor masses, but it also resulted in nanoparticle internalization by the cancer cells at a microscopic level.

"This ability to accumulate iron oxide nanoparticles within cancerous cells following systemic administration has important implications for diagnostic and therapeutic applications of this particular type of magnetic nanomaterial," said Griswold.

The multidisciplinary Dartmouth studies utilized a broad variety of Dartmouth's Shared Resources for scientific investigation including the Dartmouth Transgenic and Genetic Construct Shared Resource; the Dartmouth Electron Microscope Facility; the Dartmouth Center for Cancer Nanotechnology Excellence, Toxicology, Biodistribution, and Pathology Core; the Dartmouth Trace Element Core; and the Dartmouth-Hitchcock Norris Cotton Cancer Center Pathology Translational Research Core. All of the Dartmouth Cores and Shared Resources are open to outside investigators by arrangement.

"In studying cancer at Dartmouth, we are committed to team science," said Griswold. "Solutions to problems like these require transdisciplinary collaborations operating at the complex interfaces between molecular biotechnology, nanotechnology, biology, and medicine."

Looking forward, the researchers are in the final stages of follow-up work synthesizing and characterizing more sophisticated iron oxide nanoparticles that are more capable of targeting the inherent heterogeneity of cell surface markers in tumor microenvironments.

See more here:
Researchers Use Nanoparticles to Selectively Target Tumor Cells in Two Cancer Models

Nanobiotix Appoints Its Manufacturing Partner, CordenPharma: Another Step Towards Commercialization

Posted on by

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces it has appointed CordenPharma as its manufacturing partner. The opening of a new manufacturing line and the scaling up of production is an important step in NBTXR3s route to commercialization.

The new manufacturing line, located in France, will increase the amount of NBTXR3 product available. With an anticipated award of a CE mark in 2016, the Company is preparing to scale-up production further to meet the needs of future commercialization. Furthermore, Nanobiotix is anticipating future demand from clinical trials in the coming years in Europe and in the United States.

CordenPharma is an international full service CMO (contract manufacturing organization) which provides specialized technologies for the development and manufacture of health products. The company is recognized by EMA and FDA thanks to its eight cGMP facilities across Europe and the United States and works with both pharma and biotech companies. Its facilities are regularly inspected by the regulatory authorities (FDA and EMA) and have a good track record.

Laurent Lvy, Chief Executive Officer at Nanobiotix, commented: Finding the right manufacturing partner is essential, since ensuring quality and sufficient levels of supply is fundamental for meeting the market demands and the growth of the Company.

Yves Michon, Prsident Synkem - CordenPharma said: Nanobiotixs product, NBTXR3 is a fascinating product not only with respect to its properties, but also in its manufacture. We are working closely with Nanobiotix to ensure a seamless process and manage the scale-up of the product.

NBTXR3 is Nanobiotixs lead product in the NanoXray portfolio. The product comprises Hafnium Oxide nanoparticles which can be injected directly into tumor. With the application of radiotherapy, these nanoparticles absorb X-rays have the potential to significantly enhances the radiation dose within the cancer cells without increasing the dose to the surrounding healthy tissues. NBTXR3 has the potential to cause a paradigm shift in cancer therapy with significant clinical benefit for patients.

In November 2014, Nanobiotix announced its global clinical development plan. In addition to Soft Tissue Sarcoma and Head and Neck cancer, the plan now includes metastatic liver cancer, hepatocellular carcinomas and prostate cancer. In the second half of 2015, the liver cancers and high risk prostate cancer programs are anticipated to enter the clinical stage.

About NANOBIOTIX: http://www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The companys first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.

Nanobiotixs lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

See the rest here:
Nanobiotix Appoints Its Manufacturing Partner, CordenPharma: Another Step Towards Commercialization

SQUALENOYLATION: a Nanomedicine Platform for the Treatment of Severe Diseases – Video

Posted on by


SQUALENOYLATION: a Nanomedicine Platform for the Treatment of Severe Diseases
Speaker: Prof. Dr. med. Patrick Couvreur, Centre d #39;tudes Pharmaceutiques (CNRS), Paris (F) "European Research Council -Related Talks on Nanomedicine and Drug Delivery" Chair: Dr. Twan ...

By: TAUVOD

See original here:
SQUALENOYLATION: a Nanomedicine Platform for the Treatment of Severe Diseases - Video

Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations

Posted on by

UCLA bioengineers develop platform that offers personalized approach to treatment

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy. And one of their greatest challenges is determining which ratio and combination -- from the large number of medications available -- is best for each individual patient.

Dr. Dean Ho, a professor of oral biology and medicine at the UCLA School of Dentistry, and Dr. Chih-Ming Ho, a professor of mechanical engineering at the UCLA Henry Samueli School of Engineering and Applied Science, have developed a revolutionary approach that brings together traditional drugs and nanotechnology-enhanced medications to create safer and more effective treatments. Their results are published in the peer-reviewed journal ACS Nano.

Chih-Ming Ho, the paper's co-corresponding author, and his team have developed a powerful new tool to address drug resistance and dosing challenges in cancer patients. The tool, Feedback System Control.II, or FSC.II, considers drug efficacy tests and analyzes the physical traits of cells and other biological systems to create personalized "maps" that show the most effective and safest drug-dose combinations.

Currently, doctors use people's genetic information to identify the best possible combination therapies, which can make treatment difficult or impossible when the genes in the cancer cells mutate. The new technique does not rely on genetic information, which makes it possible to quickly modify treatments when mutations arise: the drug that no longer functions can be replaced, and FSC.II can immediately recommend a new combination.

"Drug combinations are conventionally designed using dose escalation," said Dean Ho, a co-corresponding author of the study and the co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the School of Dentistry. "Until now, there hasn't been a systematic way to even know where the optimal drug combination could be found, and the possible drug-dose combinations are nearly infinite. FSC.II circumvents all of these issues and identifies the best treatment strategy."

The researchers demonstrated that combinations identified by FSC.II could treat multiple lines of breast cancer that had varying levels of drug resistance. They evaluated the commonly used cancer drugs doxorubicin, mitoxantrone, bleomycin and paclitaxel, all of which can be rendered ineffective when cancer cells eject them before they have had a chance to function.

The researchers also studied the use of nanodiamonds to make combination treatments even more effective. Nanodiamonds -- byproducts of conventional mining and refining operations -- have versatile characteristics that allow drugs to be tightly bound to their surface, making it much harder for cancer cells to eliminate them and allowing toxic drugs to be administered over a longer period of time.

The use of nanodiamonds to treat cancer was pioneered by Dean Ho, a professor of bioengineering and member of the UCLA Jonsson Comprehensive Cancer Center and the California NanoSystems Institute.

"This study has the capacity to turn drug development, nano or non-nano, upside-down," he said. "Even though FSC.II now enables us to rapidly identify optimized drug combinations, it's not just about the speed of discovering new combinations. It's the systematic way that we can control and optimize different therapeutic outcomes to design the most effective medicines possible."

Continue reading here:
Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations

How to introduce Nanomedicine Products and bring their Impact to the Market? – Video

Posted on by


How to introduce Nanomedicine Products and bring their Impact to the Market?
Speaker: Dr. Christopher R. Anzalone, Ph.D., President and CEO, Arrowhead Research Corporation Pasadena, CA (USA) CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.

By: TAUVOD

See the rest here:
How to introduce Nanomedicine Products and bring their Impact to the Market? - Video


  1. Nanomedicine